Scientific journal
European Student Scientific Journal
ISSN 2310-3094
ISSN 2310-3094
NEW GENERATION OF DRUGS FOR HYPERTENSION
177 KB
Today hypertension is a very widespread disease, especially among people over 40 years old. It occurs on the average in 10-20 % of adult population. In the absence of treatment hypertension leads to the development of such cardiovascular diseases, as stroke, ischemic heart disease and heart failure. Therefore it is necessary to intake regularly the drugs stabilizing pressure and preventing the development of negative aftereffects. The up-to-date medicine permanently is in search of creating the new drugs combining advantages such as a high effectiveness and a minimum of side effects. It is necessary to define such drugs, as Zophenopril (angiotensin converting enzyme inhibitors), Eprosartan (angiotensin ІІ receptor blockers) and Lercanidipin (calcium channel blockers). Zophenopril differs from other ACE inhibitors by its high cardioprotective activity due to its special properties: high lipophility, an expressed antioxidant activity and cardioselectivity. Eprosartan and Lercanidipin should be marked for the presence of such properties, as high effectiveness, selectivity, metabolic neutrality and a good tolerance.
hypertension
Zophenopril
Eprosartan
Lercanidipin